Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)

References

• American cancer Society. Cancer facts and figures. Atlanta (GA): American Cancer Society; 2016
   Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidents and deaths to 2030; the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• Available from: https://seer.cancer.gov/statfacts/html/pancreas.html
   Google Scholar
• Rishi A, Goggins M, Wood LD, et al. Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol. 2015 Feb;42(1):28–39.
   PubMed Web of Science ®Google Scholar
• Chandana S, Mahadevan D. Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype? Expert Rev Mol Med. 2009 Nov 17;11.
   PubMed Web of Science ®Google Scholar
• Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998 Jan;18(1):38–43.
   PubMed Web of Science ®Google Scholar
• Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998 Feb;16(2):670–682.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Sep 11;371(11):1039–1049.
   PubMed Web of Science ®Google Scholar
• Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology. 2010 Oct;139(4):1076–1080.
   PubMed Web of Science ®Google Scholar
• Lal G, Liu G, Schmocker B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res. 2000;60:409–416.
   PubMed Web of Science ®Google Scholar
• Couch FJ, Johnson MR, Rabe K, et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005;65:383–386.
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009;27:433–438.
   PubMed Web of Science ®Google Scholar
• Salo-Mullen EE, O’Reilly EM, Kelsen DP, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015;121:4382–4388.
   PubMed Web of Science ®Google Scholar
• Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148:556–564.
   PubMed Web of Science ®Google Scholar
• Woollard PM, Mehta NA, Vamathevan JJ, et al. The application of next-generation sequencing technologies to drug discovery and development. Drug Discov Today. 2011 Jun;16(11–12):512–519.
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806.
   PubMed Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399–405.
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.
   PubMed Web of Science ®Google Scholar
• Roberts NJ, Norris AL, Petersen GM, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2015;6(2):166–175.
   PubMed Web of Science ®Google Scholar
• Dreyer SB, Chang DK, Bailey P, et al. Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clin Cancer Res. 2017;23(7):1638–1646.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185–203.
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007 Apr;6(4):1186–1197.
   PubMed Web of Science ®Google Scholar
• Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–1178.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–503.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546–1558.
   PubMed Web of Science ®Google Scholar
• Andor N, Graham TA. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22:105–113.
   PubMed Web of Science ®Google Scholar
• Yachida S, Jones S, Bozic L, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–1117.
   PubMed Web of Science ®Google Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009 Apr 9;458(7239):719–724.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Jones M, Zheng Z, Wang J, et al. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointest Endosc. 2016 Jan;83(1):140–148.
   PubMed Web of Science ®Google Scholar
• Springer S, Wang Y, Dal Molin M, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015 Nov;149(6):1501–1510.
   PubMed Web of Science ®Google Scholar
• Valero V 3rd, Saunders TJ, He J, et al. Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing: implications for surgical management. Ann Surg. 2016 Jan;263(1):153–161.
   PubMed Web of Science ®Google Scholar
• Wright GP, Chesla DW, Chung MH. Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma. Am J Surg. 2016 Mar;211(3):506–511.
   PubMed Web of Science ®Google Scholar
• Sibinga Mulder BG, Mieog JSD, Farina Sarasqueta A, et al. Diagnostic value of targeted next-generation sequencing in patients with suspected pancreatic or periampullary cancer. J Clin Pathol. 2018 Mar;71(3):246–252.
   PubMed Web of Science ®Google Scholar
• Barrett MT, Deiotte R, Lenkiewicz E, et al. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer. 2017 Aug 8;117(4):572–582.
   PubMed Web of Science ®Google Scholar
• Aung KL, Fischer SE, Denroche RE, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2017 Dec 29. DOI:10.1158/1078-0432.CCR-17-2994
   Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized triall. J Clin Oncol. 1997 Jun;15(6):2403–2413.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Ouyang G, Liu Z, Huang S, et al. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. World J Surg Oncol. 2016;14:59.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the central European cooperative oncology group. J Clin Oncol. 2007;25(16):2212.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Schüll B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol. 2003;14(1):97.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. Lancet. 2016;387(10018):545.
   PubMed Web of Science ®Google Scholar
• Lim SM, Westover KD, Ficarro SB, et al. Therapeutic targeting of oncogenic K-RAS by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014;53:199–204.
   PubMed Web of Science ®Google Scholar
• Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005;23(5):485–487.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22(8):1430–1438.
   PubMed Web of Science ®Google Scholar
• Yuan TL, Fellmann C, Lee CS, et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 2014 Oct;4(10):1182–1197.
   PubMed Web of Science ®Google Scholar
• Xue W, Dahlman JE, Tammela T, et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA. 2014 Aug 26;111(34):E3553–61.
   PubMed Web of Science ®Google Scholar
• Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002;2:243–247.
   PubMed Web of Science ®Google Scholar
• Zorde Khvalevsky E, Gabai R, Rachmut IH, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20723–20728.
   PubMed Web of Science ®Google Scholar
• Golan T, Khvalevsky E, Hubert A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6:24560–24570.
   PubMed Web of Science ®Google Scholar
• Pecot CV, Wu SY, Bellister S, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014;13:2876–2885.
   PubMed Web of Science ®Google Scholar
• Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15(6):489–500.
   PubMed Web of Science ®Google Scholar
• Muzumdar MD, Chen PY, Dorans KJ, et al. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun. 2017 Oct 23;8(1):1090.
   PubMedGoogle Scholar
• Moore MJ, Goldstein D, Hamm J, et al. National cancer institute of Canada clinical trials group. erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2007 May 20;25(15):1960–1966.
   PubMed Web of Science ®Google Scholar
• Chou A, Waddell N, Cowley MJ, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013 Aug 31;5(8):78.
   PubMed Web of Science ®Google Scholar
• Harder J, Ihorst G, Heinemann V, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012 Mar 13;106(6):1033–1038.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hylander BL, LeVea C, et al. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models. Br J Cancer. 2014 Jan 21;110(2):320–329.
   PubMed Web of Science ®Google Scholar
• Ma WW, Fetterly G, LeVEa C, et al. A phase Ib study of the FGFR/VEGFR inhibitor dovitinib (D) combined with gemcitabine(G) and Capecitabine (C) in advanced pancreatic cancer patients. Eur J Cancer. 2015;51:S438.
   Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731–739.
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ, Rolfo CD, Lie SV, et al. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. J Clin Oncol. 2018 36:4_suppl, 521- 521.
   Web of Science ®Google Scholar
• Singhi AD, Ali SM, Lacy J, et al. Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2017 May;15(5):555–562.
   PubMed Web of Science ®Google Scholar
• Yan HH, Jung KH, Son MK, et al. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Oncotarget. 2014 Oct 15;5(19):9150–9168.
   PubMedGoogle Scholar
• Kessler ER, Eckhardt SG, Pitts TM, et al. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs. 2016 Apr;34(2):176–183.
   PubMed Web of Science ®Google Scholar
• Middleton G, Palmer DH, Greenhalf W, et al. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncol. 2017 Apr;18(4):486–499.
   PubMed Web of Science ®Google Scholar
• Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014;50(12):2072–2081.
   PubMed Web of Science ®Google Scholar
• Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012;30(3):1216.
   PubMed Web of Science ®Google Scholar
• Pettazzoni P, Viale A, Shah P, et al. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 2015;75(6):1091–1101.
   PubMed Web of Science ®Google Scholar
• Mirzoeva OK, Collisson EA, Schaefer PM, et al. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013;12(10):2213–2225.
   PubMed Web of Science ®Google Scholar
• Brauswetter D, Gurbi B, Varga A, et al. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. PLoS One. 2017 Sep 28;12(9):e0185687.
   PubMed Web of Science ®Google Scholar
• Kordes S, Klümpen HJ, Weterman MJ, et al. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2015 Jun;75(6):1135–1141.
   PubMed Web of Science ®Google Scholar
• Chung V, McDonough S, Philip PA, et al. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol. 2017 Apr 1;3(4):516–522.
   PubMed Web of Science ®Google Scholar
• Klümpen HJ, Queiroz KC, Spek CA, et al. mTOR inhibitor treatment of pancreatic cancer in a patient with peutz-jeghers syndrome. J Clin Oncol. 2011 Feb 20;29(6).
   PubMed Web of Science ®Google Scholar
• Driscoll DR, Karim SA, Sano M, et al. mTORC2 signaling drives the development and progression of pancreatic cancer. Cancer Res. 2016;76:6911–6923.
   PubMed Web of Science ®Google Scholar
• Conway JRW, Warren SC, Herrmann D, et al. Intravital imaging to monitor therapeutic response in moving hypoxic regions resistant to PI3K pathway targeting in pancreatic cancer. Cell Rep. 2018;23(11):3312–3326.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726–736.
   PubMed Web of Science ®Google Scholar
• Stine RR. Matunis EL JAK-STAT signaling in stem cells. Adv Exp Med Biol. 2013;786:247–267.
   PubMed Web of Science ®Google Scholar
• Fukuda A, Wang SC, Morris JP 4th, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011 Apr 12;19(4):441–455.
   PubMed Web of Science ®Google Scholar
• Denley SM, Jamieson NB, McCall P, et al. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:887–898.
   PubMed Web of Science ®Google Scholar
• Nagathihalli NS, Castellanos JA, Shi C, et al. STAT3 mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of pancreatic cancer. Gastroenterology. 2015;149:1932–1943.e9.
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Starodub A, BaEl-Rayes BF, et al. A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts). J clin oncol. 2017;35(15_suppl):4106.
   Google Scholar
• Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, double-blind, phase ii study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015 Dec 1;33(34):4039–4047.
   PubMed Web of Science ®Google Scholar
• Franco J, Balaji U, Freinkman E, et al. Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities. Cell Rep. 2016 Feb 9;14(5):979–990.
   PubMed Web of Science ®Google Scholar
• Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007 Feb 1;67(3):1030–1037.
   PubMed Web of Science ®Google Scholar
• Li C, Wu JJ, Hynes M, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011 Dec;141(6):2218–2227.
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007 Sep 13;1(3):313–323.
   PubMed Web of Science ®Google Scholar
• Rasheed Z, Wang Q, Matsui W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp. 2010; (43): e2169 - e2169.
   Google Scholar
• Bailey JM, Alsina J, Rasheed ZA, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology. 2014 Jan;146(1):245–256.
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Ohuchida K, Sada M, et al. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells. PLoS One. 2014 Sep 15;9(9):e107247.
   PubMed Web of Science ®Google Scholar
• Bao B, Azmi AS, Aboukameel A, et al. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. J Biol Chem. 2014 May 23;289(21):14520–14533.
   PubMed Web of Science ®Google Scholar
• Skoda J, Hermanova M, Loja T, et al. Co-expression of cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma. PLoS One. 2016;11(7):e0159255.
   PubMed Web of Science ®Google Scholar
• Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. Nat Med. 2013;19:1410–1422.
   PubMed Web of Science ®Google Scholar
• Rucki AA, Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol. 2014;20:2237–2246.
   PubMed Web of Science ®Google Scholar
• Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455:406–410.
   PubMed Web of Science ®Google Scholar
• Catenacci DV, Junttila MR, Karrison T, et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol. 2015 Dec 20;33(36):4284–4292.
   PubMed Web of Science ®Google Scholar
• Madden J. Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. Cambridge (MA): Infinity Pharmaceuticals; 2012.
   Google Scholar
• Ko AH, LoConte N, Tempero MA, et al. A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas. 2016 Mar;45(3):370–375.
   PubMed Web of Science ®Google Scholar
• Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7:678–689.
   PubMed Web of Science ®Google Scholar
• Gao J, Long B, Wang Z. Role of Notch signaling pathway in pancreatic cancer. Am J Cancer Res. 2017 Feb 1;7(2):173–186.
   PubMed Web of Science ®Google Scholar
• Buchler P, Gazdhar A, Schubert M, et al. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg. 2005;242:791–800.
   PubMed Web of Science ®Google Scholar
• Doucas H, Mann CD, Sutton CD, et al. Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J Surg Oncol. 2008;97:63–68.
   PubMed Web of Science ®Google Scholar
• Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol. 2010 Sep;27(3):1017–1022.
   PubMed Web of Science ®Google Scholar
• De Jesus-Acosta A, Laheru D, Maitra A, et al. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs. 2014 Aug;32(4):739–745.
   PubMed Web of Science ®Google Scholar
• Cook N, Basu B, Smith DM, et al. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer. 2018;118:793–801.
   Web of Science ®Google Scholar
• Zhang Y, Morris JP 4th, Yan W, et al. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013 Aug 1;73(15):4909–4922.
   PubMed Web of Science ®Google Scholar
• White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gatrointestinal cancers. Gastroenterology. 2012;142:219–232.
   PubMed Web of Science ®Google Scholar
• Jiang X, Hao H-X, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2013;110:12649–12654.
   PubMed Web of Science ®Google Scholar
• Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717–11722.
   PubMed Web of Science ®Google Scholar
• Chantrill LA, Nagrial AM, Watson C, et al. Australian pancreatic cancer genome initiative (APGI); individualized molecular pancreatic cancer therapy (IMPaCT) trial management committee of the Australasian gastrointestinal trials group (AGITG). Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res. 2015 May 1;21(9):2029–2037.
   PubMed Web of Science ®Google Scholar
• Kim H, Saka B, Knight S, et al. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res. 2014 Apr 1;20(7):1865–1872.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Kelsen DP, Capanu M, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018;89:19–26.
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Lee JW, Lowery MA, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018;124:1374–1382.
   Web of Science ®Google Scholar
• Ayars M, Eshleman J, Goggins M. Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle. 2017 May 19;16(10):991–998.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Jiao L, Chang P, et al. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res. 2008;14:2042–2048.
   PubMed Web of Science ®Google Scholar
• Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013 Jan;62(1):112–120.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Beck JT, et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016 Jun 15;22(12):2848–2854.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018 Feb 1;36(4):359–366.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, McDonough S, Philip PA, et al. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). J Clin Oncol. 2018 36:4_suppl, 208-208.
   Web of Science ®Google Scholar
• Vennin C, Chin VT, Warren SC, et al. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci Transl Med. 2017 Apr 5;9(384).
   PubMed Web of Science ®Google Scholar
• Qi J. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure. Cold Spring Harb Perspect Biol. 2014;6:a018663.
   PubMed Web of Science ®Google Scholar
• Mazur PK, Herner A, Mello SS, et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015;21:1163–1171.
   PubMed Web of Science ®Google Scholar
• Sahai V, Kumar K, Knab LM, et al. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther. 2014;13:1907–1917.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Tateishi K, Kudo Y, et al. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progres-sion of human pancreatic cancer. Oncotarget. 2016;7(38):61469–61484.
   PubMedGoogle Scholar
• Binker MG, Binker-Cosen AA, Gaisano HY, et al. TGF-β1 increases invasiveness of SW1990 cells through Rac1/ROS/NF-κB/IL-6/MMP-2. Biochem Biophys Res Commun. 2011 Feb 4;405(1):140–145.
   PubMed Web of Science ®Google Scholar
• Binker-Cosen MJ, Richards D, Oliver B, et al. Palmitic acid increases invasiveness of pancreatic cancer cells AsPC-1 through TLR4/ROS/NF-κB/MMP-9 signaling pathway. Biochem Biophys Res Commun. 2017 Feb 26;484(1):152–158.
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first line therapy for patients with unresectable pancreatic cancer – A randomized trial. J Clin Oncol. 2001b;19:3447–3455.
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87(2):161–167.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2003;21(17):3296–3302.
   PubMed Web of Science ®Google Scholar
• Eric Van Cutsem E, Lenz H, Furuse J, et al. Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: primary analysis of the randomized, double-blind phase III MAESTRO study. J Clin Oncol. 2016 34:4_suppl, 193-193.
   Web of Science ®Google Scholar
• Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci USA. 2013;110(30):12325–12330.
   PubMed Web of Science ®Google Scholar
• Picozzi VJ, Pipas JM, Koong AC, et al. FG-3019, a human monoclonal antibody to connective tissue growth factor, combined with chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. J Cancer Clin Trials. 2017;2:123.
   Google Scholar
• Picozzi VJ, Rocha FG, Helton S, et al. Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC). J Clin Oncol. 2018 36:4_suppl, 365-365.
   Google Scholar
• Pothula SP, Xu Z, Goldstein D, et al. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Br J Cancer. 2016 Feb 2;114(3):269–280.
   PubMed Web of Science ®Google Scholar
• Pothula SP, Xu Z, Goldstein D, et al. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. Oncotarget. 2017 Sep 11;8(44):76722–76739.
   PubMedGoogle Scholar
• Chen L, Flies D. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–242.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Łuksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Nov 23;551(7681):512–516.
   PubMed Web of Science ®Google Scholar
• Connor AA, Denroche RE, Jang GH, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol. 2017 Jun 1;3(6):774–783.
   PubMed Web of Science ®Google Scholar
• Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018 Jan 24. DOI:10.1158/1078-0432.CCR-17-3099
   Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010 Oct;33(8):828–833.
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013 Sep;36(7):382–389.
   PubMed Web of Science ®Google Scholar
• Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014 Jul;153(1):145–152.
   PubMed Web of Science ®Google Scholar
• Okudaira K, Hokari R, Tsuzuki Y, et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol. 2009 Oct;35(4):741–749.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000 Jan;67(1):2–17.
   PubMed Web of Science ®Google Scholar
• He S, Zhao H, Fei M, et al. Expression of the co-signaling molecules CD40-CD40l and their growth inhibitory effect on pancreatic cancer in vitro. Oncol Rep. 2012;28:262–268.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Torigian DA, Chiorean EG, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013 Nov 15;19(22):6286–6295.
   PubMed Web of Science ®Google Scholar
• Lim SY, Yuzhalin AE, Gordon-Weeks AN, et al. Targeting the CCL2-CCR2 signaling axis in cancer. Oncotarget. 2016 May 10;7(19):28697–28710.
   PubMedGoogle Scholar
• Sanford DE, Belt BA, Panni RZ, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013 Jul 1;19(13):3404–3415.
   PubMed Web of Science ®Google Scholar
• Nywening TM, Wang-Gillam A, Sanford DE, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016 May;17(5):651–62.NoelM.
   PubMed Web of Science ®Google Scholar
• Lowery M, Ryan D, Wolpin B, et al. Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma. Ann Oncol. 2017 Sep 1;28(suppl_5):mdx369.132.
   Google Scholar
• Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005 Mar;11(3):312–319.
   PubMed Web of Science ®Google Scholar
• Bahary N, Garrido-Laguna I, Cinar P, et al. Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: interim analysis. J clin oncol. 2016;34(15_suppl):3020.
   Web of Science ®Google Scholar
• Geng R, Li Z, Li S, et al. Proteomics in pancreatic cancer research. Int J Proteomics. 2011;2011:365350.
   PubMedGoogle Scholar
• Jimenez-Luna C, Torres C, Ortiz R, et al. Proteomic biomarkers in body fluids associated with pancreatic cancer. Oncotarget. 2018;9(23):16573–16587.
   PubMedGoogle Scholar
• Humphery-Smith I. A human proteome project with a beginning and an end. Proteomics. 2004;4:2519–2521.
   PubMed Web of Science ®Google Scholar
• Mueller M, Martens L, Apweiler R. Annotating the human proteome: beyond establishing a parts list. Biochim Biophys Acta. 2007;1774:175–191.
   PubMed Web of Science ®Google Scholar
• Humphrey ES, Su SP, Nagrial AM, et al. Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Mol Cell Proteom. 2016;15:2671–2685.
   PubMed Web of Science ®Google Scholar
• Brandi J, Pozza ED, Dando I, et al. Secretome protein signature of human pancreatic cancer stem-like cells. J Proteom. 2016;136:1–12.
   PubMed Web of Science ®Google Scholar
• Brandi J, Dando I, Pozza ED, et al. Proteomic analysis of pancreatic cancer stem cells: functional role of fatty acid synthesis and mevalonate pathways. J Proteom. 2017;150:310–322.
   PubMed Web of Science ®Google Scholar
• Park J, Lee E, Park KJ, et al. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Oncotarget. 2017;8:42761–42771.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Elliott VL, Evans A, et al. Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus. Clin Cancer Res. 2016;22:1734–1743.
   PubMed Web of Science ®Google Scholar
• Britton D, Zen Y, Quaglia A, et al. Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS ONE. 2014;9.
   Web of Science ®Google Scholar
• Makohon-Moore AP, Zhang M, Reiter JG, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017;49:358–366.
   PubMed Web of Science ®Google Scholar
• Kim MS, Zhong Y, Yachida S, et al. Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Mol Cell Proteom. 2014;13:2803–2811.
   PubMed Web of Science ®Google Scholar
• Tape CJ, Ling S, Dimitriadi M, et al. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell. 2016;165:1818.
   PubMed Web of Science ®Google Scholar
• Wang X, Niu J, Li J, et al. Temporal effects of combined birinapant and paclitaxel on pancreatic cancer cells investigated via large-scale, ion-current-based quantitative proteomics (IonStar) mol. Cell Proteom. 2018;17:655–671.
   PubMed Web of Science ®Google Scholar
• Cartwright TH, Parisi M, Espirito JL, et al. Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC). J clin oncol. 2017;35(15 suppl):e18147–e18147.
   Google Scholar
• Reni M, Balzano G, Zanon S, et al. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer. 2016;115(3):290–296.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle M, Xiao L, et al. A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs): updated survival analysis. J Clin Oncol. 2018 36:4_suppl, 350-350..
   Web of Science ®Google Scholar
• Golan T, Oh D, Reni M, et al. POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm). J Clin Oncol. 2016;34(suppl; abstr TPS4152):TPS4152-TPS4152.
   Google Scholar
• Borazanci EH, Guarnieri C, Haag S, et al. Retrospective analysis of patients using olaparib (O) in pancreatic cancer (PC). J Clin Oncol. 2018 36:4_suppl, 389-389 .
   Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244–250.
   PubMed Web of Science ®Google Scholar
• Weterings E, Gallegos AC, Dominick LN, et al. A novel small molecule inhibitor of the DNA repair protein Ku70/80. DNA Repair (Amst). 2016;43:98–106.
   PubMed Web of Science ®Google Scholar
• Fell VL, Schild-Poulter C. Ku regulates signaling to DNA damage response pathways through the Ku70 von Willebrand A domain. Mol Cell Biol. 2012 Jan;32(1):76–87.
   PubMed Web of Science ®Google Scholar
• Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014 Jun 16;25(6):735–747.
   PubMed Web of Science ®Google Scholar
• Riley CJ, Engelhardt KP, Saldanha JW, et al. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res. 2009 Mar 1;69(5):1933–1940.
   PubMed Web of Science ®Google Scholar
• Johnson B, Mahadevan D. Emerging role and targeting of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in human malignancies. Clin Cancer Drugs. 2015 Feb;2(2):100–111.
   PubMedGoogle Scholar
• Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2(2):133–143.
   PubMed Web of Science ®Google Scholar
• Kleger A, Perkhofer L, Seufferlein T. Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol. 2014 Jul;25(7):1260–1270.
   PubMed Web of Science ®Google Scholar
• Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015;9:4479–4499.
   PubMed Web of Science ®Google Scholar
• Babiker HM, Zahid U, Howe CL, et al. Analyzing the efficacy and safety of immunotherapy in pancreatic ductal adenocarcinoma (PDA): a systematic review and meta-analysis. J clin oncol. 2018 Feb 1;36(4_suppl):512.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–2543.
   PubMed Web of Science ®Google Scholar
• Benavides M, Guillen C, Rivera F, et al. PANOVA: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma—updated efficacy results. J Clin Oncol. 2017;35(15_suppl):e15790–e15790.
   Google Scholar